Dianthus posts interim Phase 3 data for claseprubart in rare nerve disorder

Filed June 11, 2026 · Period ending June 12, 2026 · ~1 min read

Key Changes

• high

  Company released interim responder analysis from first 40 patients completing Part A of Phase 3 CAPTIVATE trial testing claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune nerve disease.

  Item 7.01 view on EDGAR →
• medium

  Data was disclosed via updated corporate presentation posted to investor relations website on June 11, 2026, rather than through formal press release or conference.

  8-K: Presentation verify on EDGAR →